Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31536852,PFS,"At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,4,16206,DB08896,Regorafenib
,31536852,OS,"The median OS was 11.5 months (95% CI, 7.0-not reached).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,11.5,16207,DB08896,Regorafenib
≥,33830408,PFS,The median PFS was significantly longer in patients achieving total trough concentrations (Ctrough) of regorafenib and M-2/M-5 ≥2.9 µg/mL than those who did not (112 vs. 57 days; p = 0.044).,Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33830408/),[μg] / [ml],2.9,23143,DB08896,Regorafenib
≥,33830408,total trough concentrations (Ctrough),The median PFS was significantly longer in patients achieving total trough concentrations (Ctrough) of regorafenib and M-2/M-5 ≥2.9 µg/mL than those who did not (112 vs. 57 days; p = 0.044).,Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33830408/),[μg] / [ml],2.9,23144,DB08896,Regorafenib
,33830408,total trough concentrations (Ctrough),The median PFS was significantly longer in patients achieving total trough concentrations (Ctrough) of regorafenib and M-2/M-5 ≥2.9 µg/mL than those who did not (112 vs. 57 days; p = 0.044).,Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33830408/),d,112,23145,DB08896,Regorafenib
,33830408,total trough concentrations (Ctrough),The median PFS was significantly longer in patients achieving total trough concentrations (Ctrough) of regorafenib and M-2/M-5 ≥2.9 µg/mL than those who did not (112 vs. 57 days; p = 0.044).,Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33830408/),d,57,23146,DB08896,Regorafenib
,33830408,Ctrough,"Conclusions Dose titration of regorafenib to achieve drug-related Ctrough levels between 2.9 and 4.3 µg/mL in Cycle 1 may improve efficacy and safety, warranting further investigation in a larger patient population.",Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33830408/),[μg] / [ml],2.9 and 4.3,23147,DB08896,Regorafenib
,23666093,AUC,Comparable reductions of the AUC to 0.69 ± 0.12 (iopromide) and 0.76 ± 0.11 (Gadomer) were found 24 hours after the therapy.,Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666093/),,0.69,36258,DB08896,Regorafenib
,23666093,AUC,Comparable reductions of the AUC to 0.69 ± 0.12 (iopromide) and 0.76 ± 0.11 (Gadomer) were found 24 hours after the therapy.,Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666093/),,0.76,36259,DB08896,Regorafenib
,23666093,Ktrans,A significant higher Ktrans was detected with iopromide (14.3 ± 2.7 mL per 100 mL/min) compared with Gadomer (1.8 ± 0.2 mL per 100 mL/min).,Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666093/),[ml] / [100·min·ml],14.3,36260,DB08896,Regorafenib
,23666093,Ktrans,A significant higher Ktrans was detected with iopromide (14.3 ± 2.7 mL per 100 mL/min) compared with Gadomer (1.8 ± 0.2 mL per 100 mL/min).,Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666093/),[ml] / [100·min·ml],1.8,36261,DB08896,Regorafenib
,34157616,MTD,The MTD was defined as 82 mg/m2.,Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34157616/),[mg] / [m2],82,59749,DB08896,Regorafenib
,31290566,PFS,In patients with no/nonsignificant gastrectomy the median PFS was 145 (interquartile range 43-281) days.,The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290566/),d,145,79966,DB08896,Regorafenib
,31290566,PFS,The PFS in patients with a major gastrectomy was 172 (interquartile range 57-280) days.,The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290566/),d,172,79967,DB08896,Regorafenib
,31290566,total concentration,The average ± standard deviation total concentration of regorafenib including the metabolites M-2 and M-5 was 6.9 ± 1.53 μmol/L and 6.7 ± 1.56 μmol/L in patient with major gastrectomy and no/nonsignificant gastrectomy respectively.,The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290566/),[μM] / [l],6.9,79968,DB08896,Regorafenib
,31290566,total concentration,The average ± standard deviation total concentration of regorafenib including the metabolites M-2 and M-5 was 6.9 ± 1.53 μmol/L and 6.7 ± 1.56 μmol/L in patient with major gastrectomy and no/nonsignificant gastrectomy respectively.,The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31290566/),[μM] / [l],6.7,79969,DB08896,Regorafenib
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95368,DB08896,Regorafenib
,26003007,progression-free survival,"Five of 9 (56%) patients had a partial response and the median progression-free survival was 7 months (range, 1.5-15.1 months).","Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26003007/),month,7,95369,DB08896,Regorafenib
,31785533,Recovery,Recovery from plasma was 81.4-90.2% and matrix effect was negligible (93.3-95.4%).,Development of a validated UPLC-MS/MS method for quantification of p38 MAPK inhibitor PH-797804: Application to a pharmacokinetic study in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31785533/),%,81.4-90.2,115619,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.6,126440,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.9,126441,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.4,126442,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.5,126443,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.2,126444,DB08896,Regorafenib
,27734608,unbound fractions,"In vitro studies showed high binding of regorafenib, M-2, and M-5 to plasma proteins, with unbound fractions of ~0.6%, ~0.9%, and ~0.4%, respectively, in murine plasma and ~0.5%, ~0.2%, and ~0.05%, respectively, in human plasma.",Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734608/),%,0.05,126445,DB08896,Regorafenib
,31471313,progression-free survival,"Stable disease was the best response in 4 patients, and median progression-free survival was 1.9 months.",Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471313/),month,1.9,151029,DB08896,Regorafenib
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],55.9,186198,DB08896,Regorafenib
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.7,186199,DB08896,Regorafenib
,30570132,AUC0-24h,"AUC0-24h for regorafenib alone was 55.9 μg·hour/mL (coefficient of variance (CV): 40%), and for regorafenib with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 μg·hour/mL (CV: 34%) and 53.6 μg·hour/mL (CV: 43%), respectively.",Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30570132/),[h·μg] / [ml],53.6,186200,DB08896,Regorafenib
,22568966,progression-free survival,"Median progression-free survival was 107 days (95% CI, 66-161).",Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22568966/),d,107,203970,DB08896,Regorafenib
,29908468,flow rate,"The chromatographic separation of nimbolide and the internal standard (regorafenib) was attained on an Aquity BEH C18 column (100 × 2.1 mm, 2.7 μm), using ACN and 0.1% of formic acid in water as mobile phase components in a gradient elution mode at a flow rate of 0.45 mL/min over a short run time of 4 min.","First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29908468/),[ml] / [min],0.45,233351,DB08896,Regorafenib
,31732439,serum concentrations,"The serum concentrations of total regorafenib for patients whose dose was escalated to 160 mg/day were significantly lower than those of the patients whose dose was not escalated (median, 3978 vs. 7244 nM; P = .027).",A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732439/),,72,270449,DB08896,Regorafenib
,31732439,serum unbound concentrations,"The serum unbound concentrations of the sum of regorafenib and the active metabolites correlated significantly with the maximum grade of regorafenib-related symptomatic adverse events in the first cycle (11,138 vs. 19,096 pM; P = .035).",A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732439/),pM,"11,138",270450,DB08896,Regorafenib
,31732439,serum unbound concentrations,"The serum unbound concentrations of the sum of regorafenib and the active metabolites correlated significantly with the maximum grade of regorafenib-related symptomatic adverse events in the first cycle (11,138 vs. 19,096 pM; P = .035).",A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31732439/),pM,"19,096",270451,DB08896,Regorafenib
